BRAF and melanoma: Since PPARGC1A silencing is expected to alter metabolic demands through impeding mitochondrial biogenesis, we used a metabolism-focused compound library to seek differential sensitivity between parental (drug naïve) and chronic treated BRAF-inhibitor resistant K029A melanoma cells (Fig. 2a).